［1］Vairy S, Garcia JL, Teira P, et al. CTL019 (tisagenlecleucel): CART therapy for relapsed and refractory Bcell acute lymphoblastic leukemia\[J\]. Drug Des Devel Ther, 2018,12: 3885-3898.

［2］Akbar AN, Henson SM, Lanna A. Senescence of T lymphocytes: implications for enhancing human immunity\[J\]. Trends Immunol, 2016,37(12): 866-876.

［3］Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy\[J\]. Mol Ther Methods Clin Dev, 2017,4: 92-101.

［4］Vormittag P, Gunn R, Ghorashian S, et al. A guide to manufacturing CAR T cell therapies\[J\]. Curr Opin Biotechnol, 2018,53: 164-181.

［5］Jiang X, Xu J, Liu M, et al. Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities\[J\]. Cancer Lett, 2019,462: 23-32.

［6］June CH, Sadelain M. Chimeric antigen receptor therapy\[J\]. N Engl J Med, 2018,379(1): 64-73.

［7］Brown C, Badie B, Barish M, et al. Bioactivity and safety of IL13Rα2redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma\[J\]. Clin Cancer Res, 2015,21(18): 4062-4072.

［8］Luo C, Wei J, Han W. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China\[J\]. Sci China Life Sci, 2016,59(4): 349-359.

［9］Li D, Li X, Zhou WL, et al. Genetically engineered T cells for cancer immunotherapy\[J\]. Signal Transduct Target Ther, 2019,4: 35.

［10］Ma S, Li X, Wang X, et al. Current progress in CART cell therapy for solid tumors\[J\]. Int J Biol Sci, 2019,15(12): 2548-2560.

［11］Remmerswaal EBM, Hombrink P, Nota B, et al. Expression of IL7Rα and KLRG1 defines functionally distinct CD8+ Tcell populations in humans\[J\]. Eur J Immunol, 2019,49(5): 694-708.

［12］Kallies A. Distinct regulation of effector and memory Tcell differentiation\[J\]. Immunol Cell Biol, 2008,86(4): 325-332.

［13］Ruffo E, Wu RC, Bruno TC, et al. Lymphocyteactivation gene 3 (LAG3): The next immune checkpoint receptor\[J\]. Semin Immunol, 2019,42: 101305.

［14］Ando M, Ito M, Srirat T, et al. Memory T cell, exhaustion, and tumor immunity\[J\]. Immunol Med, 2020,43(1): 1-9.

［15］Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells\[J\]. J Clin Invest, 2005,115(6): 1616-1626.

［16］Nolz J, StarbeckMiller G, Harty J. Naive, effector and memory CD8 Tcell trafficking: parallels and distinctions\[J\]. Immunotherapy, 2011,3: 1223-1233.

［17］BarEphraim YE, Koning JJ, Burniol Ruiz E, et al. CD62L is a functional and phenotypic marker for circulating innate lymphoid cell precursors\[J\]. J Immunol, 2019,202(1): 171-182.

［18］Watson HA, Durairaj RRP, Ohme J, et al. Lselectin enhanced T cells improve the efficacy of cancer immunotherapy\[J\]. Front Immunol, 2019,10: 1321.

［19］Kalbasi A, Shrimali RK, Chinnasamy D, et al. Prevention of interleukin2 withdrawalinduced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor Tcell receptor and an antiapoptotic protein\[J\]. J Immunother, 2010,33(7): 672-683.

［20］Cui G, Staron MM, Gray SM, et al. IL7induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity\[J\]. Cell, 2015,161(4): 750-761.

［21］Adachi K, Kano Y, Nagai T, et al. IL7 and CCL19 expression in CART cells improves immune cell infiltration and CART cell survival in the tumor\[J\]. Nat Biotechnol, 2018,36(4): 346-351.

［22］Nolz JC, Richer MJ. Control of memory CD8+ T cell longevity and effector functions by IL15\[J\]. Mol Immunol, 2020,117: 180-188.

［23］Zhou J, Jin L, Wang F, et al. Chimeric antigen receptor T(CART) cells expanded with IL7/IL15 mediate superior antitumor effects\[J\]. Protein Cell, 2019,10(10): 764-769.

［24］Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by antiCD19 chimeric antigen receptor T cells are associated with high serum interleukin15 levels\[J\]. J Clin Oncol, 2017,35(16): 1803-1813.

［25］Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferonα2, interleukin (IL)2, IL15, IL21, and IL12\[J\]. Semin Oncol, 2015,42(4): 539-548.

［26］Moroz A, Eppolito C, Li Q, et al. IL21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL2, IL15, and IL21\[J\]. J Immunol, 2004,173(2): 900-909.

［27］Sim GC, Radvanyi L. The IL2 cytokine family in cancer immunotherapy\[J\]. Cytokine Growth Factor Rev, 2014,25(4): 377-390.

［28］Ptckov P, Musil J, tach M, et al. A new approach to CAR Tcell gene engineering and cultivation using piggyBac transposon in the presence of IL4, IL7 and IL21\[J\]. Cytotherapy, 2018,20(4): 507-520.

［29］Sabatino M, Hu J, Sommariva M, et al. Generation of clinicalgrade CD19specific CARmodified CD8+ memory stem cells for the treatment of human Bcell malignancies\[J\]. Blood, 2016,128(4): 519-528.

［30］Chapuis AG, Roberts IM, Thompson JA, et al. Tcell therapy using interleukin21primed cytotoxic Tcell iymphocytes combined with cytotoxic Tcell lymphocyte antigen4 blockade results in longterm cell persistence and durable tumor regression［J］. J Clin Oncol, 2016,34(31): 3787-3795.

［31］Li L, Wan S, Tao K, et al. KLRG1 restricts memory T cell antitumor immunity\[J\]. Oncotarget, 2016,7(38): 61670-61678.

［32］Nakajima M, Sakoda Y, Adachi K, et al. Improved survival of chimeric antigen receptorengineered T(CART) and tumorspecific T cells caused by antiprogrammed cell death protein 1 singlechain variable fragmentproducing CART cells\[J\]. Cancer Sci, 2019,110(10): 3079-3088.

［33］Horton BL, Williams JB, Cabanov A, et al. Intratumoral CD8+ Tcell apoptosis is a major component of Tcell dysfunction and impedes antitumor immunity\[J\]. Cancer Immunol Res, 2018,6(1): 14-24.

［34］Mardiana S, Solomon BJ, Darcy PK, et al. Supercharging adoptive T cell therapy to overcome solid tumorinduced immunosuppression\[J\]. Sci Transl Med, 2019,11(495): eaaw2293.

［35］Wang X, Berger C, Wong CW, et al. Engraftment of human central memoryderived effector CD8+ T cells in immunodeficient mice\[J\]. Blood, 2011,117(6): 1888-1898.

［36］Klebanoff CA, Gattinoni L, TorabiParizi P, et al. Central memory self/tumorreactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells\[J\]. Proc Natl Acad Sci U S A, 2005,102(27): 9571-9576.

［37］Gattinoni L, Speiser DE, Lichterfeld M, et al. T memory stem cells in health and disease［J］. Nat Med, 2017,23(1): 18-27.

［38］Lee JM. When CAR meets stem cells\[J\]. Int J Mol Sci, 2019,20(8): 1825.

［39］Wu F, Zhang W, Shao H, et al. Human effector T cells derived from central memory cells rather than CD8+T cells modified by tumorspecific TCR gene transfer possess superior traits for adoptive immunotherapy［J］. Cancer Lett, 2013,339(2): 195-207.

［40］Xu Y, Zhang M, Ramos CA, et al. Closely related Tmemory stem cells correlate with in vivo expansion of CAR.CD19T cells and are preserved by IL7 and IL15\[J\]. Blood, 2014,123(24): 3750-3759.

［41］Wang X, Popplewell L, Wagner J, et al. Phase Ⅰ studies of centralmemoryderived CD19 CAR T cell therapy following autologous HSCT in patients with Bcell NHL\[J\]. Blood, 2016,127(24): 2980-2990.

［42］Gattinoni L, Klebanoff C, Restifo N. Paths to stemness: building the ultimate antitumour T cell\[J\]. Nat Rev Cancer, 2012,12(10): 671-684.